PMV Pharmaceuticals Inc
NASDAQ:PMVP

  • LAST PRICE
    2.1000
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    1.9600/ 75
  • Ask / Lots
    2.2200/ 1
  • Open / Previous Close
    0.0000 / 2.1000
  • Day Range
    ---
  • 52 Week Range
    1.1750
    9.7200
  • Volume
    ---

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Yesterday

      Show headlines and story abstract

    • 23 hours ago by GlobeNewswire
      Companies Mentioned: PMVP

    • 23 hours ago by Dow Jones
      Companies Mentioned: PMVP
      Total current liabilities 12,058 14,029 Operating lease liabilities, noncurrent 12,142 12,434 -------- ---------- Total liabilities 24,200 26,463 -------- ---------- Stockholders' equity: Additional paid-in capital 538,078 545,468 Accumulated deficit (325,273) (310,003) Accumulated other comprehensive (loss) income (129) 224 -------- ---------- Total stockholders' equity 212,676 225,689 -------- ---------- Total liabilities and stockholders' equity $ 236,876 $ 252,152 ======== ========== PMV Pharmaceuticals, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) (in thousands, except share and per share amounts) Three Months Ended March 31, ---------------------------------- 2024 2023 ---------------- ------------ Operating expenses: Research and development $ 13,186 $ 15,073 General and administrative 5,035 6,407 ------------ ----------- Total operating expenses 18,221 21,480 ------------ ----------- Loss from operations (18,221) (21,480) Other income (expense): Interest income, net 2,952 2,325 Other income (expense), net (1) 27 ------------ ----------- Total other income (expense) 2,951 2,352 ------------ ----------- Loss before income taxes (15,270) (19,128) Income taxes -- -- ------------ ----------- Net loss (15,270) (19,128) Unrealized (loss) gain on available for sale investments, net of tax (319) 329 Foreign currency translation loss (34) -- ------------ ----------- Comprehensive loss $ (15,623) $ (18,799) ============ =========== Net loss per share -- basic and diluted $ (0.30) $ (0.42) Weighted-average common shares outstanding 51,445,862 45,773,357

    • 23 hours ago by Dow Jones
      Companies Mentioned: PMVP
      Total current liabilities 12,058 14,029 Operating lease liabilities, noncurrent 12,142 12,434 -------- ---------- Total liabilities 24,200 26,463 -------- ---------- Stockholders' equity: Additional paid-in capital 538,078 545,468 Accumulated deficit (325,273) (310,003) Accumulated other comprehensive (loss) income (129) 224 -------- ---------- Total stockholders' equity 212,676 225,689 -------- ---------- Total liabilities and stockholders' equity $ 236,876 $ 252,152 ======== ========== PMV Pharmaceuticals, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) (in thousands, except share and per share amounts) Three Months Ended March 31, ---------------------------------- 2024 2023 ---------------- ------------ Operating expenses: Research and development $ 13,186 $ 15,073 General and administrative 5,035 6,407 ------------ ----------- Total operating expenses 18,221 21,480 ------------ ----------- Loss from operations (18,221) (21,480) Other income (expense): Interest income, net 2,952 2,325 Other income (expense), net (1) 27 ------------ ----------- Total other income (expense) 2,951 2,352 ------------ ----------- Loss before income taxes (15,270) (19,128) Income taxes -- -- ------------ ----------- Net loss (15,270) (19,128) Unrealized (loss) gain on available for sale investments, net of tax (319) 329 Foreign currency translation loss (34) -- ------------ ----------- Comprehensive loss $ (15,623) $ (18,799) ============ =========== Net loss per share -- basic and diluted $ (0.30) $ (0.42) Weighted-average common shares outstanding 51,445,862 45,773,357

  • Apr 12, 2024

Peers Headlines